Dmpl Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 4 Months
- Last Filing with ROC 31 Mar 2020
- Revenue Growth 431.72%
- Profit Growth -9891.02%
- Ebitda -9881.93%
- Net Worth -479.85%
- Total Assets 0.69%
About Dmpl Pharmaceuticals
Dmpl Pharmaceuticals Private Limited (DPPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 October 2016 (Eight years and four months 3 days old ). Its registered office is in Thane, Maharashtra, India.
The Corporate was formerly known as Genesun Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Company Details
-
Location
Thane, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74999MH2016PTC286559
-
Company No.
286559
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
05 Oct 2016
-
Date of AGM
31 Dec 2020
-
Date of Balance Sheet
31 Mar 2020
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Dmpl Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikesh Upadhyay
|
Additional Director | 09-Jan-2017 | Current |
|
Sunny Upadhaya
|
Director | 05-Oct-2016 | Current |
Financial Performance of Dmpl Pharmaceuticals.
Dmpl Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 431.72% increase. The company also saw a substantial fall in profitability, with a 9891.02% decrease in profit. The company's net worth observed a substantial decline by a decrease of 479.85%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dmpl Pharmaceuticals?
In 2020, Dmpl Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Vms Offshore Services Private LimitedVikesh Upadhyay is a mutual person
-
Varren Maritime Academy FoundationSunny Upadhaya and Vikesh Upadhyay are mutual person
-
Varren Marines Shipping Private LimitedVikesh Upadhyay is a mutual person
-
Dmpl Healthcare Private LimitedSunny Upadhaya is a mutual person
-
Varren Education Foundation
Vikesh Upadhyay is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dmpl Pharmaceuticals?
Unlock and access historical data on people associated with Dmpl Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dmpl Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dmpl Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
